Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced presentations at two upcoming medical meetings. Details of the presentations are as follows:
https://mma.prnewswire.com/media/1333752/Nanoscope_Therapeutics_Logo.jpg
Bascom Palmer Eye Institute's 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting
Title: Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results from a Long-Term Follow-Up Study (REMAIN)Session Title: Inherited Retinal DegenerationsSession Date:Saturday,February 8, 2025Session Time:6:25 p.m. ETPresenter:Allen Ho,MD, FACS, FASRS, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital, and Chief Medical Advisor of Nanoscope
Dr. Ho will participate in a panel discussion on inherited retinal dystrophies (IRDs), for several of which, Nanoscope is developing restorative treatments. As part of this, Dr. Ho will discuss 126-week data from Nanoscope's REMAIN long-term follow-up study of advancedretinitis pigmentosa patients dosed in the RESTORE randomized controlled trial.
The Macula Society 48th Annual Meeting
Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Topline Results from the REMAIN Follow-Up Study (REMAIN)Session Title: Inherited Retinal Dystrophy ISession Date:Thursday,February 13, 2025Session Time: 7:05 a.m. ETPresenter: Victor Gonzalez, MD, Gulf Coast Eye Institute and REMAIN trial investigator
Dr. Gonzalez will present and discuss long-term follow-up efficacy and safety data of Nanoscope's MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa.
AboutNanoscope Therapeutics Inc.Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase2bmulticenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate aBLA submission for MCO-010 to treat RPin Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate aPhase 3 registrational trialin Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.
Investor Contact:Argot Partners212-600-1902PR@nanostherapeutics.com
https://c212.net/c/img/favicon.png?sn=DA11655&sd=2025-02-04
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentations-at-upcoming-medical-meetings-302368064.html
SOURCE Nanoscope Therapeutics
https://rt.newswire.ca/rt.gif?NewsItemId=DA11655&Transmission_Id=202502041605PR_NEWS_USPR_____DA11655&DateId=20250204